VJOncology is committed to improving our service to you

BTOG 2018 | Lung cancer immunotherapy: the need for predictive biomarkers

VJOncology is committed to improving our service to you

James Spicer

As explained here by James Spicer, PhD, FRCP, of Guy’s and St Thomas’ NHS Foundation Trust, London, UK, the field of lung cancer research is currently dominated by immunotherapy. Prof. Spicer highlights the need for predictive biomarkers, such as tumor mutational burden (TMB), to determine response to these agents and how this is more complex than it seems. This video was recorded at the British Thoracic Oncology Group (BTOG) Annual Conference 2018, held in Dublin, Ireland.

Share this video  

Sign-up for our Newsletter!

Keep up to date with all the latest news with our monthly newsletter